Top Ten most popular articles on Pharmafile.com this week
pharmafile | July 28, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | biotech, drugs, healthcare, pharma, pharmaceutical, top 10
It’s Friday, and it’s been a week characterised by a range of promising research results, particularly into HIV and Duchenne muscular dystrophy. But this all fell into shadow; by far, the biggest news this week was the release of AstraZeneca’s long-awaited data from it’s Mystic trial into lung cancer. The company is still reeling from the news, whcih caused more than $10 billion to be wiped from its market value.
Check out the week’s ten most popular articles on Pharmafile.com now!
If you’ve ever taken a course of antibiotics then you will be familiar with the piece of advice that is often handed out alongside the prescription – to make sure you complete the full course of the antibiotics. A new study emerged, published in the BMJ has countered this by suggesting that this direction is not based on evidence.
New research, led by teams from AFM-Telethon laboratory in Nantes and the University of London, have developed a gene therapy for Duchenne muscular dystrophy (DMD) that has shown significant promise in treating the muscle-wasting disease.
The latest Phase 3 data investigating Janssen’s darunivir in the treatment of human immunodeficiency virus (HIV-1) showed that the drug was effective and safe, Janssen has announced.
Mitsubishi Tanabe Pharma (MTPC) has announced that it has moved to acquire Israeli pharma company, NeuroDerm, in a deal worth $1.1 billion.
The Central Drugs Standard Control Organisation (CDSCO) tested drugs to determine whether they were of standard quality but found that 946 of the medicines across 66 companies failed the test.
The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and only available therapy to target the IL-17 receptor in the treatment of moderate-to-severe plaque psoriasis in candidates for systemic therapy.
In a press conference at the White House, President Trump, alongside representatives from Corning, MSD and Pfizer, announced that 1,000 jobs would be created in a new pharmaceutical glass packaging initiative.
It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the company, claiming it had made false claims to improve sales of two drugs.
GSK continue its appointment spree with a particularly notable staff acquisition, with leading immuno-oncology scientist, Dr Laurie Glimcher, joining its Board of Directors.
The long-awaited results for AstraZeneca’s Mystic trial have been revealed and, in a shocking setback for the company, it was found that its injectable immunotherapy treatments do not outperform standard chemotherapy.
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …